The **NMN vs NR** debate is one of the most common questions in longevity science. NAD+ (nicotinamide adenine dinucleotide) declines approximately 50% between ages 40 and 60, a drop linked to mitochondrial dysfunction, impaired DNA repair, and reduced sirtuin activity. Two supplements dominate the NAD+ precursor market: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Understanding the differences between NMN vs NR is essential for choosing the right supplement for your longevity stack.
**Mechanism of Action: NMN vs NR at the Molecular Level**
Both NMN and NR are precursors that the body converts into NAD+. NR is first phosphorylated to NMN by the enzyme NRK, then NMN is converted to NAD+ by NMNAT enzymes. NMN skips the NRK step, which theoretically makes it a more direct precursor. However, recent research shows NMN may need to be converted to NR to enter some cell types via the SLC12A8 transporter debate, complicating the "more direct" argument.
**Clinical Evidence for NR (Evidence Grade B)**
NR has more published human RCTs in the NMN vs NR comparison. The CHROMAVIT trial showed NR supplementation (1000mg/day) increased NAD+ levels by 40-50% in healthy adults. Elysium's BASIS study demonstrated sustained NAD+ elevation over 8 weeks. Martens et al. (2018) showed NR supplementation improved blood pressure trends in healthy middle-aged adults. However, no RCT has yet shown hard clinical endpoints like reduced disease incidence or mortality.
**Clinical Evidence for NMN (Evidence Grade B-C)**
NMN human trials are catching up. A 2022 study in *Science* showed 250mg/day NMN improved muscle insulin sensitivity in prediabetic women. A Japanese RCT by Igarashi et al. demonstrated that 250mg NMN improved sleep quality and reduced fatigue in older adults. However, the total body of human evidence remains smaller than NR. Dr. Alejandro Marti, a [board-certified plastic surgeon](https://bonitas.clinic) and longevity researcher, includes NMN in his personal supplement protocol at 500mg sublingual daily based on the current evidence.
**Bioavailability: A Key Differentiator in the NMN vs NR Debate**
Sublingual NMN delivery may bypass first-pass metabolism, potentially achieving higher blood levels faster. NR is well-absorbed orally but undergoes significant hepatic metabolism. Some studies suggest that at high doses, both compounds face a ceiling effect where additional supplementation does not further increase NAD+. The bioavailability question remains one of the most active areas of research in the NMN vs NR comparison.
**Cost and Practical Considerations**
NMN is typically more expensive (40-80 EUR/month at 500mg/day) versus NR (30-50 EUR/month at 300mg/day). NR has FDA GRAS status in the US. NMN was briefly caught in regulatory uncertainty but remains widely available in Europe and internationally.
**The Verdict on NMN vs NR**
Both raise NAD+ effectively. NR has a larger evidence base from human trials. NMN may have a slight bioavailability edge when taken sublingually. For most people, the choice comes down to cost and form factor. Neither has demonstrated life extension in humans yet, so the evidence grade for longevity outcomes remains C for both. The optimal approach may be to choose either one and combine it with other evidence-backed longevity interventions — exercise, sleep optimization, and nutrition — rather than agonizing over marginal differences between NMN vs NR.
---
**References:**
1. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. *Science*, 372(6547), 1224-1229. 2. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. *Nature Communications*, 9(1), 1286. 3. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. *NPJ Aging*, 8(1), 5. 4. Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic potential of NAD-boosting molecules. *Cell Metabolism*, 27(3), 529-547. 5. Conze D, Brenner C, Kruger CL. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial. *Scientific Reports*, 9(1), 9772.